Drugs / High-Dose Quadrivalent Influenza Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04537234 | Nov 2020 → Feb 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04498832 | Oct 2020 → Jan 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-Dose Quadrivalent Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04537234 ↗ |
| Modality | Vaccine | “high dose quadrivalent influenza vaccine” NCT04498832 ↗ |
| Route | Intramuscular | “Route of administration: IM” NCT04498832 ↗ |